Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Hilgers, 2002, ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease, J Am Soc Nephrol, 13, 1100, 10.1681/ASN.V1341100

Kunz, 2008, Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease, Ann Intern Med, 148, 30, 10.7326/0003-4819-148-1-200801010-00190

Remuzzi, 2006, Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes, J Clin Invest, 116, 288, 10.1172/JCI27699

Gerstein, 2001, Albuminuria and cardiovascular events, death and heart failure in diabetic and non-diabetic individuals, J Am Med Ass, 286, 421, 10.1001/jama.286.4.421

Phillips, 2007, Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials, Arch Intern Med, 167, 1930, 10.1001/archinte.167.18.1930

2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317

Teo, 2004, Am Heart J, 148, 52, 10.1016/j.ahj.2004.03.020

Stevens, 2006, Assessing kidney function—measured and estimated glomerular filtration rate, N Engl J Med, 354, 2473, 10.1056/NEJMra054415

Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161

Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303

Barnett, 2004, Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy, N Engl J Med, 351, 1952, 10.1056/NEJMoa042274

Jafar, 2003, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis, Ann Intern Med, 139, 244, 10.7326/0003-4819-139-4-200308190-00006

Bakris, 2000, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?, Arch Int Med, 160, 685, 10.1001/archinte.160.5.685

Casas, 2005, Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis, Lancet, 366, 2026, 10.1016/S0140-6736(05)67814-2

Mann, 2003, Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study, Am J Kidney Dis, 42, 936, 10.1016/j.ajkd.2003.07.015

Matchar, 2008, Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension, Ann Intern Med, 148, 16, 10.7326/0003-4819-148-1-200801010-00189

Nakao, 2003, Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial, Lancet, 361, 117, 10.1016/S0140-6736(03)12229-5

Kunz, 2008, The COOPERATE trial: a letter of concern, Lancet, 371, 1575, 10.1016/S0140-6736(08)60681-9